Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF, 107K) PPT slides of all figures Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Krause, A. Articles by Sadelain, M. Search for Related Content PubMed PubMed Citation Articles by Krause, A. Articles by Sadelain, M. Social Bookmarking                            What's this?

Articles

Anja Krause^*, Hong-Fen Guo, Jean-Baptiste Latouche^*, Cuiwen Tan^*, Nai-Kong V. Cheung, and Michel Sadelain^*,

From the ^* Department of Human Genetics, Department of Pediatrics, and Immunology Program, Memorial Sloan-Kettering Cancer Center, New York 10021

Most tumor cells function poorly as antigen-presenting cells in part because they do not express costimulatory molecules. To provide costimulation to T lymphocytes that recognize tumor cells, we constructed a CD28-like receptor specific for G_D2, a ganglioside overexpressed on the surface of neuroblastoma, small-cell lung carcinoma, melanoma, and other human tumors. Recognition of G_D2 was provided by a single-chain antibody derived from the G_D2-specific monoclonal antibody 3G6. We demonstrate that the chimeric receptor 3G6-CD28 provides CD28 signaling upon specific recognition of the G_D2 antigen on tumor cells. Human primary T lymphocytes retrovirally transduced with 3G6-CD28 secrete interleukin 2, survive proapoptotic culture conditions, and selectively undergo clonal expansion in the presence of an antiidiotypic antibody specific for 3G6-CD28. Polyclonal CD8⁺ lymphocytes expressing 3G6-CD28 are selectively expanded when cultured with cells expressing allogeneic major histocompatibility complex class I together with G_D2. Primary T cells given such an antigen-dependent survival advantage should be very useful to augment immune responses against tumor cells.

Key Words: adoptive cell therapy • chimeric receptors • costimulation • ganglioside • gene transfer

Abbreviations used: GAM, goat anti–mouse; GAR, goat anti– rat; LNGFR, low-affinity nerve growth factor receptor; NTP, inactive mutant form of the human LNGFR; scFv, single chain variable region fragment.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

• Emtage, P. C.R., Lo, A. S.Y., Gomes, E. M., Liu, D. L., Gonzalo-Daganzo, R. M., Junghans, R. P. (2008). Second-Generation Anti-Carcinoembryonic Antigen Designer T Cells Resist Activation-Induced Cell Death, Proliferate on Tumor Contact, Secrete Cytokines, and Exhibit Superior Antitumor Activity In vivo: A Preclinical Evaluation. Clin. Cancer Res. 14: 8112-8122 [Abstract] [Full Text]  
• Kowolik, C. M., Topp, M. S., Gonzalez, S., Pfeiffer, T., Olivares, S., Gonzalez, N., Smith, D. D., Forman, S. J., Jensen, M. C., Cooper, L. J.N. (2006). CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor Enhances In vivo Persistence and Antitumor Efficacy of Adoptively Transferred T Cells.. Cancer Res. 66: 10995-11004 [Abstract] [Full Text]  
• Willemsen, R. A., Ronteltap, C., Chames, P., Debets, R., Bolhuis, R. L. H. (2005). T Cell Retargeting with MHC Class I-Restricted Antibodies: The CD28 Costimulatory Domain Enhances Antigen-Specific Cytotoxicity and Cytokine Production. J. Immunol. 174: 7853-7858 [Abstract] [Full Text]  
• Gyobu, H., Tsuji, T., Suzuki, Y., Ohkuri, T., Chamoto, K., Kuroki, M., Miyoshi, H., Kawarada, Y., Katoh, H., Takeshima, T., Nishimura, T. (2004). Generation and Targeting of Human Tumor-Specific Tc1 and Th1 Cells Transduced with a Lentivirus Containing a Chimeric Immunoglobulin T-Cell Receptor. Cancer Res. 64: 1490-1495 [Abstract] [Full Text]  
• Finney, H. M., Akbar, A. N., Lawson, A. D. G. (2004). Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCR{zeta} Chain. J. Immunol. 172: 104-113 [Abstract] [Full Text]  
• Gorlick, R., Anderson, P., Andrulis, I., Arndt, C., Beardsley, G. P., Bernstein, M., Bridge, J., Cheung, N.-K., Dome, J. S., Ebb, D., Gardner, T., Gebhardt, M., Grier, H., Hansen, M., Healey, J., Helman, L., Hock, J., Houghton, J., Houghton, P., Huvos, A., Khanna, C., Kieran, M., Kleinerman, E., Ladanyi, M., Lau, C., Malkin, D., Marina, N., Meltzer, P., Meyers, P., Schofield, D., Schwartz, C., Smith, M. A., Toretsky, J., Tsokos, M., Wexler, L., Wigginton, J., Withrow, S., Schoenfeldt, M., Anderson, B. (2003). Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: Meeting Summary. Clin. Cancer Res. 9: 5442-5453 [Abstract] [Full Text]  
• Krause, A., Scaletta, N., Ji, J.-D., Ivashkiv, L. B. (2002). Rheumatoid Arthritis Synoviocyte Survival Is Dependent on Stat3. J. Immunol. 169: 6610-6616 [Abstract] [Full Text]  
• Haynes, N. M., Trapani, J. A., Teng, M. W. L., Jackson, J. T., Cerruti, L., Jane, S. M., Kershaw, M. H., Smyth, M. J., Darcy, P. K. (2002). Rejection of Syngeneic Colon Carcinoma by CTLs Expressing Single-Chain Antibody Receptors Codelivering CD28 Costimulation. J. Immunol. 169: 5780-5786 [Abstract] [Full Text]  
• Haynes, N. M., Trapani, J. A., Teng, M. W. L., Jackson, J. T., Cerruti, L., Jane, S. M., Kershaw, M. H., Smyth, M. J., Darcy, P. K. (2002). Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100: 3155-3163 [Abstract] [Full Text]  
• Rossig, C., Bollard, C. M., Nuchtern, J. G., Rooney, C. M., Brenner, M. K. (2002). Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 99: 2009-2016 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS